<DOC>
	<DOCNO>NCT02511509</DOCNO>
	<brief_summary>Electroconvulsive therapy use clinical practice since 1938 , number randomize trial find significant difference favor ECT response rate individual depression receive real sham ECT . Results early study perform patient schizophrenia n't clear , trial find appreciable difference real sham ECT clinical outcome . The recent , reliable study find ECT efficacious different symptom might present course schizophrenia , example , psychotic affective one , well suicidality . The serious complication electroconvulsive therapy rare , however , frequent side effect may include cognitive impairment postictal delirium . Thus , researcher try develop new , effective less harmful procedure ECT , like bifrontal electrode . The available study reveal bifrontal ECT equal efficacy bitemporal ECT less cognitive impairment , literature examine placement limit major depressive disorder result inconsistent . In worldwide literature lack study regard use bifrontal ECT among patient schizophrenia . It interesting bifrontal ECT would affect axial symptom schizophrenia , since electrode procedure place brain area responsible negative symptom . This randomized , double blind study go ass whether bifrontal ECT effective treatment positive negative symptom schizophrenia , less harmful impact cognitive function decrease frequency severity postictal delirium compare bitemporal ECT . Moreover , first worldwide ass brain dopaminergic activity use PET patient schizophrenia ECT impact ECT concentration neurotrophins brain-derived neurotrophic factor-BDNF , neuron specific enolase-NSE protein S100B .</brief_summary>
	<brief_title>Bifrontal Bitemporal Electroconvulsive Therapy ( ECT ) Treatment Patients With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>The patient meet Diagnostic Statistical ManualDSMV criterion schizophrenia ( apart residual type ) The patient qualify ECT accord standard protocol Antipsychotic treatment dibenzepins accord follow scheme : dose clozapine high 450mg , dose olanzapine high 20mg dose quetiapine high 600mg per day If need concomitant treatment allow hydroxyzine ( max . 100mg per day ) lorazepam ( max . 4mg per day ) Anaesthesia conduct use suxamethonium chloride , propofol atropine The lack patient 's consent Mental retardation confirm psychological psychiatric examination ( IQ &lt; 70 ; fulfil DSMV criterion mental retardation ) Dementia diagnose basis DSMV criterion Substance abuse year prior study enrolment substance addiction The presence symptom meet DSMV criterion affective episode ( episode mania , hypomania depression ) The ECT conduct 6 month prior study enrolment The history previous ineffective ECT The need antipsychotic treatment derivative dibenzothiazepines dose high 450mg clozapine , 20mg olanzapine 600mg quetiapine per day The woman generative period use effective contraception ( sexual abstinence , contraceptive , intrauterine device , mechanical contraceptive device ) The need use suxamethonium chloride , propofol atropine anaesthetic concomitant medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Electroconvulsive Therapy</keyword>
	<keyword>Bifrontal ECT</keyword>
	<keyword>Bitemporal ECT</keyword>
	<keyword>Cognitive function</keyword>
	<keyword>Postictal delirium</keyword>
</DOC>